Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients

• Published in: Zhōnghuá zhŏngliú zázhì Vol. 28; no. 11; p. 848
• Main Authors: Li, Hui-ping, Ma, Li-wen, Zhang, Shu-lan, Jia, Ting-zhen, Deng, Hui-jing, Zhang, Zhao-hui, Liang, Li, Wang, Mo-pei, Xiao, Yu, Cao, Bao-shan, Chen, Sen, Wang, You-fan
• Format: Journal Article
• Language: Chinese
• Published: China 01.11.2006
• Subjects: Adult; Age Factors; Amenorrhea - blood; Amenorrhea - chemically induced; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - surgery; Carcinoma, Ductal, Breast - drug therapy; Carcinoma, Ductal, Breast - surgery; Chemotherapy, Adjuvant; Disease-Free Survival; Estradiol - blood; Female; Follicle Stimulating Hormone - blood; Follow-Up Studies; Humans; Middle Aged; Premenopause; Retrospective Studies
• ISSN: 0253-3766

A retrospective analysis of 160 pre-menopausal breast cancer patients was carried out to elucidate the the menstrual outcome in those cases who had undergone adjuvant chemotherapy after surgery, and evaluate the relationship between chemotherapy-induced amenorrhea (CIA) and recurrence of the disease. 160 pre-menopausal breast cancer patients were collected, 62/159 (39.0%) of them were node positive, 91/158 (57.6%) were ER positive, and 95/155 (61.3%) were PR positive. 111 cases had infiltrative ductal carcinoma, 26 cases had infiltrative lobular carcinoma, and 22 cases with others. In 152 cases data were collected by face-to-face interview and 8 cases by phone conversation. Types and cycles of chemotherapy regimen as well as menstrual abnormalities were recorded before, during, and after chemotherapy completion. Follow up duration was 12-72 months after chemotherapy completion for all patients. 107 (66.9%) developed CIA, 24 cases returned to normal menses (22.4%), 83 cases continued CIA during more than 12-mo